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1684-1182/Copyright ª 2015, TaiwanAbstract Background: The fourth-generation human immunodeficiency virus (HIV) combina-
tion assay, which can simultaneously detect the presence of anti-HIV antibody and HIV antigen,
has been shown to shorten the window period in HIV diagnosis compared with the third-
generation HIV antibody immunoassay. This study was aimed to determine the performance
of HIV combination assays in Taiwan, where the HIV-1 seroprevalence is 0.007% and HIV-2
infection has never been reported.
Methods: Performance of three fourth-generation HIV Ag/Ab combination assays (Dia.Pro,
Wantai, and Bio-Rad) and one third-generation HIV Ab immunoassay (AxSYM HIV 1/2 gO) was
assessed.
Results: A total of 152 specimens, including 86 confirmed HIV-seropositive and 66 HIV-
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combination assays in Taiwan, Journto 100%, and specificity varied from 98.5% to 100%. Performance of the 75 equivocal samples, the
HIV status of which was confirmed later, in terms of negative prediction varied from 81.8% to
87.5%. The Bio-Rad and Dia.Pro assays exhibited higher sensitivity for the detection of p24 an-
tigen among the three fourth-generation HIV combination assays.
Conclusion: The three fourth-generation HIV Ag/Ab combination assays exhibited better sensi-
tivity, specificity, and negative prediction than the third-generation HIV Ab immunoassay.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Human immunodeficiency virus (HIV), the causative agent
of AIDS, can be transmitted through sexual transmission,
intravenous drug use (IDU), blood transfusion, and maternal
vertical transmission.1 According to the Joint United Na-
tions Program on HIV/AIDS, it has been shown that, in 2013,
about 35 million adults and children were infected and
living with HIV, and 1.5 million people died of AIDS around
the world.2 By the end of 2014, 29,665 people were living
with HIV in Taiwan and about 4600 people died of AIDS.3
The HIV-1 seroprevalence is about 0.007%, and HIV-2
infection has never been reported in Taiwan.4 Prior to
2004, sexual transmission was the major route of HIV
infection in Taiwan, with subtype B circulating among men
who have sex with men (MSM), and subtypes B and
CRF01_AE in patients infected through heterosexual trans-
mission.5,6 An outbreak of CRF07_BC among intravenous
drug users was observed in 2004,7,8 and its spread was
rapidly controlled by the harm reduction program initiated
in 2005 by the Taiwan Centers for Disease Control.9 By the
end of 2014, the cumulative proportion of HIV transmission
routes in Taiwan was 47.37% for MSM, 23.78% for IDU, and
18.53% for heterosexual behavior.3 In addition, an increase
of new HIV infections in MSM, accompanied by a decrease of
that among IDUs, was observed.4,9
Previous studies have strongly suggested that an early
use of combined highly active antiretroviral therapy
(HAART) can significantly reduce sexual transmission of
HIV, which consequently has a preventive effect on HIV
infection.10,11 Therefore, an early diagnosis of HIV infec-
tion followed by antiretroviral therapy is critical for dis-
ease control. The principles of HIV serodiagnosis were
mainly based on enzymatic immunoassay, by detecting
the presence of anti-HIV antibody. The early first- and
second-generation HIV immunoassays were designed to
capture human anti-HIV immunoglobulin G (IgG) antibody
by HIV viral lysate and HIV recombinant antigens,
respectively.12 The third-generation HIV immunoassay
showed improved ability to detect both human anti-HIV
IgM and human anti-HIV IgG antibodies.12,13 Neverthe-
less, during acute HIV infection, many patients are
asymptomatic, and antibodies against HIV are absent in
spite of the presence of HIV viral antigens (e.g., p24) and
viral RNA in blood.12,14 This period is the so-called “win-
dow period” or “seroconversion window.” Thus, fourth-
generation HIV Ag/Ab combination immunoassays, which
can simultaneously detect the presence of anti-HIVChang C-K, et al., Evaluation of
al of Microbiology, Immunology anantibodies and HIV antigens, have been expected to
shorten the window period.15e19 Currently, several com-
mercial fourth-generation combination assays are avail-
able and used worldwide.19,20 Many studies compared the
performance of fourth-generation combination assays
with that of third-generation HIV immunoassays, and tried
to validate the application of the fourth-generation as-
says in clinical use.13,15,21,22 The reports showed that
most fourth-generation assays presented high sensitivity
and specificity, and could detect seroconversion more
than 2 days earlier than third-generation assays, leading
to a reduction of the seroconversion window.13,15,23
However, the detection sensitivity of p24 antigen varied
significantly between different fourth-generation combi-
nation assays.13,15,21,22
In Taiwan, where the HIV-1 seroprevalence is about
0.007% and the third-generation HIV immunoassays are the
major HIV screening tests used in most hospitals and
voluntary HIV counseling and testing sites, the performance
of the fourth-generation combination assays is unclear and
needs to be evaluated. In this study, we evaluated the
sensitivity, specificity, and negative predictive value of
three fourth-generation combination assays (Dia.Pro,
Wantai, and Bio-Rad) and compared with those of one
third-generation HIV immunoassay (AxSYM HIV 1/2 gO).
Hence, this study was aimed to provide some practical
advices on HIV diagnostic setting in Taiwan.Materials and methods
Specimen collection
The study specimens included 86 HIV-seropositive speci-
mens, 66 HIV-seronegative specimens, and 75 specimens
with equivocal results by HIV screening test. The 86 plasma
samples, which were confirmed for HIV-1 infection by
western blot assay (New LAV Blot I; Bio-Rad, Marnes La
Coquette, France), were provided by Centers for Disease
Control in Taiwan. Sixty-six HIV-seronegative plasma sam-
ples were found to be negative by a routine HIV screening
test (AxSYM HIV 1/2 gO; Abbott GmbH & Co. KG,
Wiesbaden-Delkenheim, Germany). Sensitivity and speci-
ficity were evaluated using these 86 HIV-1-seropositive and
66 HIV-1-seronegative samples. The HIV status of 75 plasma
samples with equivocal results in HIV screening test was
later confirmed by HIV RNA viral load using the Cobas
Amplicor HIV-1 Monitor Test, version 1.5 (Roche Diagnosticsperformance of human immunodeficiency virus antigen/antibody
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.009
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blot assay at later time points with a median follow-up
period of 37 days (range 5e247 days).
Third-generation HIV antibody assay
AxSYM HIV 1/2 gO (Abbott GmbH & Co. KG), the third-
generation HIV antibody assay used in this study, can detect
HIV antibodies against HIV-1 group M, HIV-1 group O, and
HIV-2 by a three-step microparticle enzyme immunoassay.
Anti-HIV antibodies, including human IgG and IgM anti-
bodies, are captured in samples by recombinant HIV
antigen-coated microparticles. Captured antibodies are
bound to biotin-labeled recombinant HIV antigens and
peptides, and detected by an antibiotin alkaline phospha-
tase conjugate. All tests were performed and interpreted in
accordance with the manufacturer’s recommendations.
The principles and procedures of this assay have been
described previously.13
Fourth-generation HIV combination assays
The fourth-generation HIV combination assays evaluated in
this study included the following: HIV (1þ2) Ag&Ab (Beijing
Wantai Bio-pharm, Beijing, China), HIV Combination Ag/Ab
enzymatic immunoassay (Bio-Rad Laboratories) and HIV
Ab&Ag [Dia.Pro, Sesto San Giovanni (MI), Italy]. These as-
says use a “sandwich” format technique for the detection
of anti-HIV antibodies. Anti-HIV antibodies are captured by
recombinant HIV antigen-coated microwells. Captured an-
tibodies are bound to peroxidase-conjugated recombinant
HIV antigens and peptides. The simultaneous detection of
p24 antigen is achieved by coating anti-p24 antibodies on
the microwells. The captured p24 antigen is bound to a
second biotin-labeled antibody, and detected by an anti-
biotin peroxidase conjugate. These assays do not distin-
guish between anti-HIV antibodies and HIV antigens present
in a sample. All tests were performed and interpreted in
accordance with the manufacturer’s recommendations.
The principles and procedures of these assays have been
described previously.17,24
Detection of p24 antigen
To evaluate the ability of the fourth-generation HIV com-
bination assays to detect p24 antigen, the p24 positive
control of each fourth-generation HIV combination assay
was serially diluted and subsequently detected by three
fourth-generation combination assays. For each panel of
serially diluted p24 antigen, the highest dilution which
could be detected by the assays was determined.
Statistical analysis
All statistical analyses were performed using SAS (version
9.2; SAS Institute Inc., Cary, NC, USA). Categorical variables
were compared using c2 or Fisher’s exact test, whereas
noncategorical variables were compared using Student t
test or ManneWhitney U test. All tests were two tailed and
a p value of <0.05 was considered significant.Please cite this article in press as: Chang C-K, et al., Evaluation of
combination assays in Taiwan, Journal of Microbiology, Immunology anResults
Sensitivity and specificity
The sensitivity and specificity of these four assays were
determined using the 86 confirmed HIV-seropositive sam-
ples and 66 HIV-seronegative samples (Table 1). The third
HIV antibody immunoassay, AxSYM HIV 1/2 gO, showed 100%
sensitivity and 100% specificity. Among the three fourth-
generation combination assays, the sensitivity varied from
98.8% to 100% and specificity from 98.5% to 100%. The
Dia.Pro combination assay showed 100% sensitivity and
100% specificity. The Wantai assay presented lower sensi-
tivity (98.8%), while the Bio-Rad assay presented lower
specificity (98.5%). In summary, the Dia.Pro combination
assay exhibited better sensitivity and specificity among the
three fourth-generation HIV combination assays.
Performance of HIV immunoassays in terms of early
prediction
Interpretation of test results in most HIV immunoassays is
based on the ratio of signal to cutoff (S/CO). Samples
tested with S/CO values 1.00 are considered reactive, and
samples with S/CO values <1.00 are considered negative.
However, there usually are some samples with S/CO values
very close to 1.00. Samples with equivocal results pose
some difficulty in clinical interpretation, and HIV infections
with a low antibody titer, which can probably present an
equivocal S/CO value of <1.00, may be regarded as sero-
negative HIV infections.
Therefore, the ability of these four assays in dis-
tinguishing 75 samples with equivocal results was evalu-
ated. Furthermore, since the HIV status of these 75 samples
was confirmed by HIV viral load or antibody responses at
later time points, we were able to compare the perfor-
mance of these four assays on early prediction. The results
of 75 equivocal samples detected by four assays are sum-
marized in Table 2. The samples tested by AxSYM HIV 1/2
gO included 57 reactive and 18 negative samples, with the
mean S/CO values of 1.30 and 0.94, respectively. More than
70% of 75 equivocal samples showed negative results when
tested by the fourth-generation combination assays: 57
samples (mean S/CO Z 0.16) in Dia.Pro, 56 samples (mean
S/CO Z 0.01) in Wantai, and 58 samples (mean S/
COZ 0.34) in Bio-Rad (Table 2). In contrast to AxSYM HIV 1/
2 gO, the fourth-generation combination assays seemed to
unambiguously differentiate between reactive and nega-
tive samples, since the S/CO values of reactive and nega-
tive samples were significantly discriminated and far from
1.00 (Figure 1). In the 2  2 X2 analysis, the difference
between the fourth-generation assays and the third-
generation assay was statistically significant by the McNe-
mar’s test (supplementary Table 1.)
Among these 75 equivocal samples, seven were
confirmed for HIV infection by HIV western blot assay or HIV
RNA viral load at later time points (median follow-up period
34 days, range 22e114 days), and 50 samples were
confirmed as HIV negative at later time points (median
follow-up period 40 days, range 5e247 days). The remaining
18 samples for which the HIV status was not confirmed laterperformance of human immunodeficiency virus antigen/antibody
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.009
Table 1 Performance of four assays on 86 HIV-1-positive samples and 66 HIV-1-negative samples
Third-generation Ab assay Fourth-generation Ag/Ab assay
AxSYM HIV 1/2 gO Dia.Pro Wantai Bio-Rad
R N R N R N R N
HIV positive (n Z 86) 86 0 86 0 85 1 86 0
HIV negative (n Z 66) 0 66 0 66 0 66 1 65
Sensitivity (95% CI), % 100 (95.8e100) 100 (95.8e100) 98.8 (93.7e99.9) 100 (95.8e100)
Specificity (95% CI), % 100 (94.6e100) 100 (94.6e100) 100 (94.6e100) 98.5 (91.8e99.9)
Ab Z antibody; Ag Z antigen; CI Z confidence interval; HIV Z human immunodeficiency virus; N Z negative; R Z reactive.
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terms of early prediction, of these four assays on the 57
equivocal samples was evaluated (Table 3). The positive
prediction values the four assays ranged from 5.6% to
11.8%. All three fourth-generation combination assays
showed better negative prediction than AxSYM HIV 1/2 gO
(81.8%), and the Bio-Rad assay showed the best perfor-
mance (87.5%). These results suggested that the fourth-
generation combination assay had better performance on
early negative prediction, which might lead to less false-
negative interpretation.
Detection of p24 antigen
The most distinct difference between the third-generation
HIV antibody immunoassay and fourth-generation HIV
combination assay is the detection of p24 antigen in the
fourth-generation HIV combination assay.17 With this char-
acteristic design, the fourth-generation combination assay
is expected to shorten the window period, since p24 anti-
gen is released prior to the production of anti-HIV antibody
in acute HIV infection.12,14 Owing to the detection of both
viral antigens and antibodies by fourth-generation combi-
nation assays, several previous studies evaluated the p24
detection sensitivity of these assays and showed that the
sensitivity in detecting p24 antigen varied significantly be-
tween different combination assays.13,15,21,22 Here, the
capability of these three fourth-generation combination
assays to detect p24 antigen was also evaluated (Table 4).
The p24 positive control of each combination assay was
twofold serially diluted. Each panel of serially diluted p24
positive control was tested by the three combination as-
says, and the end point was determined by the highest
detectable dilution. Bio-Rad and Dia.Pro combination as-
says showed better performance than Wantai in two panels
of diluted p24 antigen. The three combination assaysTable 2 Results of 75 equivocal samples when tested by four a
Third-generation Ab assay
AxSYM HIV 1/2 gO Dia.P
Reactive 57 18
Mean S/CO (95% CI) 1.30 (1.23e1.36) 10.81
Negative 18 57
Mean S/CO (95% CI) 0.94 (0.92e0.95) 0.16 (
Ab Z antibody; Ag Z antigen; CI, confidence interval; HIV Z human
Please cite this article in press as: Chang C-K, et al., Evaluation of
combination assays in Taiwan, Journal of Microbiology, Immunology anexhibited the same ability to detect Wantai p24 antigen. In
summary, Dia.Pro and Bio-Rad showed better performance
in detecting p24 antigen.
Discussion
In this study, we compared the sensitivity and specificity of
three fourth-generation HIV combination assays with one
third-generation HIV antibody immunoassay. In addition,
performance on early prediction and p24 antigen detection
sensitivity of the three fourth-generation combination as-
says were evaluated. Our results suggested that among the
three fourth-generation HIV combination assays, the Dia.-
Pro combination assay exhibited both better sensitivity and
better specificity, whereas Wantai and Bio-Rad assays
showed lower sensitivity and lower specificity, respectively.
Nevertheless, the fourth-generation combination assay had
better performance on early negative prediction, which
might result in a reduction of false-negative interpretation.
During acute HIV infection, anti-HIV antibodies are often
produced during the first 3e5 weeks after infection.13,25,26
In most HIV antibody immunoassays, low anti-HIV antibody
response at the initiation of acute HIV infection might
cause equivocal results, which often leads to an ambiguity
in data interpretation and difficulty in clinical diagnosis.
Hence, acute HIV infections with low or developing anti-
body response might be missed by HIV antibody immuno-
assays due to the results that are equivocal but <1.00.
Consequently, this could probably lead to a delayed treat-
ment and an increased risk of transmission of HIV.11
Therefore, with the combined detection of p24 antigen,
which is a viral core protein often detectable prior to an-
tibodies, the fourth-generation combination assays may
exhibit better ability in reducing the false-negative inter-
pretation. As it has been shown in this study, the fourth-
generation combination assays significantly discriminatedssays
Fourth-generation Ag/Ab assay
ro Wantai Bio-Rad
19 17
(7.46e14.16) 4.17 (3.21e5.14) 5.08 (3.74e6.42)
56 58
0.14e0.18) 0.05 (0.01e0.09) 0.34 (0.27e0.41)
immunodeficiency virus; S/CO Z ratio of signal to cutoff.
performance of human immunodeficiency virus antigen/antibody
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.009
Table 4 Ability of three fourth-generation HIV combina-
tion assays to detect p24 antigen
Dia.Pro Wantai Bio-Rad
Highest dilution detectable
Dia.Pro p24 Ag 2 1 2
Wantai p24 Ag 32 32 32
Bio-Rad p24 Ag 8 2 8
HIV Z human immunodeficiency virus.
Figure 1. Distinct S/CO distribution of 75 equivocal samples
by the fourth-generation combination assays. (A) S/CO distri-
bution of samples (n Z 57), which showed S/CO values 1.00
by AxSYM HIV 1/2 gO, using the fourth-generation combination
assays. (B) S/CO distribution of samples (n Z 18), which
showed S/CO values <1.00 by AxSYM HIV 1/2 gO, using the
fourth-generation combination assays. HIV Z human immu-
nodeficiency virus; S/CO Z signal to cutoff ratio.
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samples with equivocal readings when tested by the third-
generation assay. Furthermore, with the HIV status being
confirmed at later time points, we could determine the
performance of these assays for early prediction. As shown
in Table 3, the fourth-generation combination assays
showed better negative prediction, leading to a reduction
of false-negative interpretation. On the other hand, the
low positive prediction (5.6e11.8%) presented by the fourTable 3 Performance of four assays on 57 equivocal
samples
AxSYM HIV
1/2 gO
Dia.Pro Wantai Bio-Rad
Sensitivity 71.4 14.2 28.6 28.6
Specificity 18 66 66 70
Positive prediction 10.9 5.6 10.5 11.8
Negative prediction 81.8 84.6 86.8 87.5
Data are presented as percentage.
HIV Z human immunodeficiency virus.
Please cite this article in press as: Chang C-K, et al., Evaluation of
combination assays in Taiwan, Journal of Microbiology, Immunology anassays demonstrate that additional tests are essential for
the confirmation of diagnosis and reduction of false-
positive interpretation.
Due to the variation in p24 antigen detection sensitivity
of different combination assays, which was reported by
several previous studies,13,15,21,22 we also compared the
p24 detection sensitivity of the three combination assays by
detecting serially diluted p24 antigen. Both Dia.Pro and Bio-
Rad assays showed better performance in detection of p24
antigen. It is interesting that each combination assay
exhibited a different ability to detect different panels of
p24 antigen, in which the highest dilution detectable
ranged from one- to 32-fold. This might result from, in
different combination assays, the varied design of the anti-
p24 antibodies or the recombinant p24 antigen used as an
antigen positive control, leading to different affinities.
Since the availability of the first fourth-generation HIV
combination assay in the late 2000s,17,27 several studies
have investigated the performance of diverse combination
assays and tried to validate their applications in clinical
use. The results of some previous studies that evaluated
these assays are briefly summarized in Table 5. In general,
the fourth-generation combination assays showed sensi-
tivity as high as 100%. Early reports indicated that, with
higher complexity than single marker antigen or antibody
assays, the fourth-generation combination assays might
compromise their specificity.17,18 Nevertheless, among
previous studies summarized in Table 5, the specificity
between different combination assays could vary from
98.0% to 99.9%, which was similar to that of third-
generation immunoassays (varied from 98.0% to
100%).13,15 The three fourth-generation combination assays
evaluated in this study also showed specificity within the
range described above, with the exception of the Wantai
combination assay presenting lower sensitivity (98.8%). The
lower sensitivity of the Wantai combination assay could be
correlated with its lower sensitivity for p24 antigen
detection.15 However, in spite of the significantly varied
sensitivity for p24 antigen detection and seroconversion
between different combination assays, the fourth-
generation combination assays were still proven to reduce
the seroconversion window by early detection of HIV
infection.13,21,28 Thus, standards for comparison of
different combination assays were recommended for vali-
dation on site.
In Taiwan, the HIV-1 seroprevalence is about 0.007%,
which is relatively low in comparison with other high-
prevalence areas in the world. On the other hand, HIV-2
infection has never been reported in Taiwan.4 Prior to 2004,performance of human immunodeficiency virus antigen/antibody
d Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.009
Table 5 Summary of studies evaluating the performance of fourth-generation combination assays
Reference Fourth-generation
assay evaluated
Sensitivity/specificity (%) p24 detection limit Reduction of
seroconversion window
Performance
of early prediction
Ly et al15 AxSYM HIV Ag/Ab Combo
Enzygnost HIV Integral
Genscreen Plus HIV Ag/Ab
Murex HIV Ag/Ab Combo
VIDAS HIV DUO
Vironostika HIV Uniform II Ag/Ab
Specificity: 99.5e99.9 3.3e>25 pg/mL 2.0e2.35 d
earlier than
third-generation assay
NA
Bourlet et al42 VIDAS HIV DUO Ultra
VIDAS HIV DUO
AxSYM HIV Ag/Ab Combo
Sensitivity: 100 Specificity:
99.03e99.86
NA VIDAS HIV DUO
Ultra detected
seroconversion earlier
NA
Kwon et al13 Architect HIV Ag/Ab Combo
AxSYM HIV Ag/Ab Combo
Elecsys 2010 HIV Combi
Specificity: 98.0e99.6 5e>25 pg/mL 4e26 d earlier than
third-generation assay
NA
Miedouge M et al21 Architect HIV Ag/Ab Combo
AxSYM HIVAg/Ab Combo
VIDAS HIV DUO Quick
VIDAS HIV DUO Ultra
NA 0.43e2.25 U/mL NA NA
Song et al22 Architect HIV Ag/Ab Combo
AxSYM HIVAg/Ab Combo
Elecsys 2010 HIV Combi
Elecsys HIV combi PT
Sensitivity:
100 Specificity:
99.0e99.6
1.13e4.50 U/mL Architect HIV Ag/Ab
Combo and Elecsys HIV
combi PT showed
earlier seroconversion (7 d)
NA
Present study Wantai HIV (1þ2) Ag&Ab
Bio-Rad HIV Combo Ag/Ab EIA
Dia.Pro HIV Ab&Ag 4th Gen.
Sensitivity:
98.8e100 Specificity:
98.5e100
Bio-Rad and Dia.
Pro showed
relatively lower
detection limit
NA Better negative
prediction than
third-generation assay
Ab Z antibody; Ag Z antigen; EIA Z enzyme immunoassay; HIV Z human immunodeficiency virus; NA Z not available.
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+ MODELsexual transmission was the major route of most HIV-1 in-
fections in Taiwan. HIV-1 subtype B and CRF01_AE are two
predominant virus strains, which account for about 70% and
25% of HIV-1 infections, respectively.5,6 However,
CRF07_BC was responsible for the outbreak of HIV-1 among
intravenous drug users between 2004 and 2005 in
Taiwan.7,8,29 In spite of the low HIV prevalence rate in
Taiwan, voluntary HIV counseling and testing sites were
launched in 1985.30 Currently, the third-generation HIV
antibody immunoassay is the major HIV screening method
used in Taiwan. It has been reported that the presence of
various infections, autoimmune diseases, vaccinations, and
hepatitis diseases can interfere with the detection capa-
bility of HIV antibody immunoassays and is likely to lead to
false-positive results.12,13,31e33 In Taiwan, a nationwide
HBV vaccination program was implemented in July 1984,
and the prevalence of chronic HBV infection among adults
born after 1984 was estimated to drop from 15e20% to
0.06%.34e36 Nevertheless, the prevalence of chronic HBV
infection among MSM, the major risk group of HIV-1 infec-
tion in Taiwan, was estimated to be 19.1%.37 Thus, the
specificity of an HIV screening test is still an important
parameter for its application in clinical diagnosis in Taiwan.
This study demonstrated that two of the three fourth-
generation combination assays had 100% specificity, as
high as that of the third-generation immunoassay evalu-
ated, which suggested the feasible application of the
fourth-generation combination assays in Taiwan.
In addition, p24 antigen is often detectable in the blood
when HIV RNA viral load is higher than 4 log10 copies/
mL,38,39 which might limit the application of the fourth-
generation combination assays in early detection of infec-
tion in some acutely infected patients.25,40,41 It has been
reported that, in the high-risk population, as compared
with the fourth-generation combination assays, nucleic
acid tests can reduce more false-negative results and could
detect HIV acute infection earlier, resulting in a decrease of
HIV transmission and subsequent cost saving on screening
tests.25 Nevertheless, the HIV-1 seroprevalence is low in
Taiwan; nucleic acid tests as the general screening test is
relatively expensive and might not be practical to use.
Hence, the fourth-generation combination assays with
relatively less cost displayed potential as a general
screening test in Taiwan.
In conclusion, this study evaluated the performance of
three fourth-generation combination assays and compared
them with one third-generation HIV antibody immunoassay.
All three fourth-generation combination assays showed
better performance for early negative prediction than the
third-generation immunoassay, and the Bio-Rad combina-
tion assay had the best negative prediction. Among the
three combination assays, the Dia.Pro combination assay
showed both better sensitivity and better specificity. In
addition, Dia.Pro and Bio-Rad assays presented better
ability to detect p24 antigen.Conflicts of interest
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